Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
Diabetes Care|April 26, 2011
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reportingCarlo Piccinni, Domenico Motola, Giulio Marchesini, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Obesity Research & Clinical Practice|March 25, 2025
Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?Angela Procacci, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
Expert Opinion on Pharmacotherapy|March 29, 2019
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?Emanuel Raschi, Elisabetta Poluzzi, Giulio Marchesini, et al.
Drug Safety|April 9, 2017
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical PracticeElisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, et al.
Pharmacological Research|March 11, 2008
The hERG K+ channel: target and antitarget strategies in drug developmentEmanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, et al.
Pharmacoepidemiology and Drug Safety|April 5, 2013
Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressantsCarlo Piccinni, Chiara Sacripanti, Elisabetta Poluzzi, et al.
Pharmacoepidemiology and Drug Safety|April 10, 2009
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, et al.
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
Diabetes Care|April 26, 2011
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reportingCarlo Piccinni, Domenico Motola, Giulio Marchesini, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Obesity Research & Clinical Practice|March 25, 2025
Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?Angela Procacci, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
Expert Opinion on Pharmacotherapy|March 29, 2019
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?Emanuel Raschi, Elisabetta Poluzzi, Giulio Marchesini, et al.
Drug Safety|April 9, 2017
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical PracticeElisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, et al.
Pharmacological Research|March 11, 2008
The hERG K+ channel: target and antitarget strategies in drug developmentEmanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, et al.
Pharmacoepidemiology and Drug Safety|April 5, 2013
Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressantsCarlo Piccinni, Chiara Sacripanti, Elisabetta Poluzzi, et al.
Pharmacoepidemiology and Drug Safety|April 10, 2009
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, et al.
Pageof 19